Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 2Sezary Syndrome 2Recurrence 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Cancers 1

Interventions

romidepsin 12Cyclophosphamide 10fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 7Gemcitabine 7Bortezomib 7fludarabine 6Lenalidomide 6Filgrastim 6tanespimycin 5Vorinostat 5Magnetic Resonance Spectroscopy 5Etoposide 5Biopsy 5belinostat 4Tacrolimus 4Depsipeptides 4Brentuximab Vedotin 4Whole-Body Irradiation 3Specimen Handling 3Radiotherapy 3Oxaliplatin 3Nivolumab 3Methylprednisolone 3Lactones 3Irinotecan 3Ipilimumab 3Doxorubicin 3Dexamethasone 3Dasatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, T-Cell, Cutaneous × 10-propargyl-10-deazaaminopterin × Clear all
NCT00554827 2020-01-03

Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Acrotech Biopharma Inc.

Phase 1 Completed
55 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT01134341 2019-12-18

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Acrotech Biopharma Inc.

Phase 1 Completed
34 enrolled
DermatologicLymphoid

Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, Primary Cutaneous Anaplastic Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡